Lankenau Medical Center , part of Main Line Health , is a 370-bed acute care , teaching hospital in Wynnewood , Pennsylvania .
7-647: Lankenau Medical Center's clinical areas include the Lankenau Heart Institute, the gastrointestinal and GI endoscopy program, cancer care services, pulmonology, orthopaedics, obstetrics and maternity, including and a level III neonatal intensive care unit, as well as minimally invasive and robotic surgery. The campus is also home to the Lankenau Institute for Medical Research and the Annenberg Center for Medical Education. Initially chartered in 1860 as
14-416: A blood test to detect it, as recognized by the 1976 Nobel Prize for Physiology or Medicine. LIMR carried out research into the role of IDO (indoleamine 2,3-dioxygenase) in cancer, including the first experimental therapeutics to directly inhibit this enzyme, which modifies inflammatory processes in cancer, autoimmune disease, retinopathy, cardiovascular disease, and other disorders. George C. Prendergast
21-478: Is credited with the discovery of the first genetic abnormality in cancer, called the Philadelphia chromosome. It is detected in the vast majority of patients suffering from myelogenous leukemia. The first molecule-targeted drug to be created for cancer therapy, Gleevec (imatinib), acts by blocking this genetic abnormality. LHRI researcher Baruch Blumberg is credited with the discovery of the hepatitis B virus and
28-772: The German Hospital of Philadelphia , the facility opened in 1866 on Morris Street in North Philadelphia . With the entry of the United States into World War I in 1917, many German institutions took new names. The German Hospital renamed itself Lankenau Hospital after John D. Lankenau , a German-born Philadelphia businessman who had been one of the hospital's first leaders. The hospital moved to larger facilities at Girard and Corinthian Avenues in North Philadelphia in 1884. In December 1953, Lankenau moved to Wynnewood on
35-710: The Main Line , occupying the site of the former Overbrook Country Club. In October 1984, the hospital joined with Bryn Mawr Hospital and the Bryn Mawr Rehabilitation Hospital under a nonprofit umbrella organization, Main Line Health . In 2010, Main Line began renovating the hospital, adding a 96-bed Heart Pavilion, dedicated to cardiovascular care, a parking garage, and a central utility plant. The expanded facilities were renamed Lankenau Medical Center. As of 2022,
42-580: The medical center has: Lankenau Institute for Medical Research Lankenau Institute for Medical Research ( LIMR ), founded in 1927, is a nonprofit, biomedical research institute located on the campus of Lankenau Medical Center in Wynnewood, Pennsylvania, serving as the research division of the Main Line Health system in suburban Philadelphia . LIMR focuses on studies of cancer, cardiovascular, autoimmune, gastrointestinal and other diseases. LIMR
49-720: Was one of the first U.S. research institutes to focus on cancer when it was founded in 1927. It was formerly known as the Lankenau Hospital Research Institute (LHRI) until 1980 and the Lankenau Medical Research Center (LMRC) from 1981-1999. Starting in 1941, LHRI also housed the Institute for Cancer Research (ICR), until the ICR was merged with the former American Oncology Hospital to create Fox Chase Cancer Center in 1974. LHRI researcher David Hungerford
#490509